Unknown

Dataset Information

0

Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.


ABSTRACT: BACKGROUND: Melphalan is one of the most active chemotherapeutic agents in the treatment of multiple myeloma (MM). However, the mechanism underlying differential patient responses to melphalan therapy is unknown. METHODS: Chromatin structure, transcriptional activity and DNA damage response signals were examined following ex vivo treatment with melphalan of both malignant bone marrow plasma cells (BMPCs) and peripheral blood mononuclear cells (PBMCs) of MM patients, responders (n=57) or non-responders (n=28) to melphalan therapy. PBMCs from healthy controls (n=25) were also included in the study. RESULTS: In both BMPCs and PBMCs, the local chromatin looseness, transcriptional activity and repair efficiency of the transcribed strand (TS) were significantly higher in non-responders than in responders and lowest in healthy controls (all P<0.05). Moreover, we found that melphalan-induced apoptosis inversely correlated with the repair efficiency of the TS, with the duration of the inhibition of mRNA synthesis, phosphorylation of p53 at serine 15 and apoptosis rates being higher in responders than in non-responders (all P<0.001). CONCLUSIONS: Our findings provide a mechanistic basis for the link between DNA repair efficiency and response to melphalan therapy. Interestingly, the observation of these phenomena in PBMCs provides a novel approach for the prediction of response to anti-myeloma therapy.

SUBMITTER: Gkotzamanidou M 

PROVIDER: S-EPMC4183844 | biostudies-other | 2014 Sep

REPOSITORIES: biostudies-other

altmetric image

Publications

Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Gkotzamanidou M M   Sfikakis P P PP   Kyrtopoulos S A SA   Bamia C C   Dimopoulos M A MA   Souliotis V L VL  

British journal of cancer 20140722 7


<h4>Background</h4>Melphalan is one of the most active chemotherapeutic agents in the treatment of multiple myeloma (MM). However, the mechanism underlying differential patient responses to melphalan therapy is unknown.<h4>Methods</h4>Chromatin structure, transcriptional activity and DNA damage response signals were examined following ex vivo treatment with melphalan of both malignant bone marrow plasma cells (BMPCs) and peripheral blood mononuclear cells (PBMCs) of MM patients, responders (n=57  ...[more]

Similar Datasets

| S-EPMC5794067 | biostudies-literature
| S-EPMC8172525 | biostudies-literature
| S-EPMC4466986 | biostudies-literature
| S-EPMC3566650 | biostudies-literature
| S-EPMC6678219 | biostudies-literature
| S-EPMC240709 | biostudies-literature
| S-EPMC4366222 | biostudies-literature
| S-EPMC4102796 | biostudies-literature
| PRJEB25605 | ENA
| S-EPMC5394869 | biostudies-literature